Hillstream BioPharma Inc. (HILS) is priced at $1.48 after the most recent trading session. At the very opening of the session, the stock price was $1.15 and reached a high price of $1.48, prior to closing the session it reached the value of $1.20. The stock touched a low price of $1.11.Recently in News on July 8, 2022, Hillstream BioPharma to Attend the 12th Annual World Orphan Drug Congress USA on July 11-13. Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, will attend the 12th Annual World Orphan Drug Congress USA 2022, being held at the Hynes Convention Center in Boston, on July 11-13, 2022. You can read further details here
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Hillstream BioPharma Inc. shares are logging -65.09% during the 52-week period from high price, and 127.69% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.65 and $4.24.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 562888 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Hillstream BioPharma Inc. (HILS) recorded performance in the market was -57.47%, having the revenues showcasing 17.46% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 15.97M, as it employees total of 1 workers.
Market experts do have their say about Hillstream BioPharma Inc. (HILS)
During the last month, 0 analysts gave the Hillstream BioPharma Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 1.1239, with a change in the price was noted -0.18. In a similar fashion, Hillstream BioPharma Inc. posted a movement of -10.84% for the period of last 100 days, recording 990,597 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for HILS is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical breakdown of Hillstream BioPharma Inc. (HILS)
Raw Stochastic average of Hillstream BioPharma Inc. in the period of last 50 days is set at 64.34%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 100.00%. In the last 20 days, the company’s Stochastic %K was 84.28% and its Stochastic %D was recorded 77.52%.
Bearing in mind the latest performance of Hillstream BioPharma Inc., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -57.47%. The shares increased approximately by 33.33% in the 7-day charts and went down by 88.73% in the period of the last 30 days. Common stock shares were driven by 17.46% during last recorded quarter.